Articles related to DRUG DISCOVERIES & DEVELOPMENT

Researchers identified a transfer RNA, tRNA¹Arg(UCU), that appears to regulate androgen receptor dependence in prostate cancer. Preclinical studies suggest manipulating this pathway may influence treatment sensitivity and the development of drug-resistant disease states.

The FDA granted Fast Track designation in September 2026 to multiple investigational oncology agents and one prostate cancer imaging strategy, highlighting continued regulatory support for therapies targeting high unmet needs across solid tumors and hematologic malignancies.

Researchers identified a previously unrecognized B7-H3-driven pathway that promotes immune suppression in castration-resistant prostate cancer. Preclinical findings suggest dual targeting of B7-H3 and MEK signaling altered the tumor microenvironment and improved antitumor activity in experimental models.

A novel liposomal drug-delivery system prolonged tetrodotoxin nerve blockade to two to three weeks in rats, substantially exceeding currently available formulations. The findings highlight a potential strategy for sustained local anesthetic delivery, although clinical relevance remains unproven pending human validation.

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.